Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIA (BioIndustry Association) welcomes move to revamp UK pre-emption policy:

This article was originally published in Clinica

Executive Summary

The UK's BioIndustry Association (BIA) has welcomed a report reviewing current pre-emption guidelines and whether they inhibit public companies from raising adequate funding from the capital markets. The BIA highlighted the report's criticism of the "blanket approach to disapplying pre-emption rights...due to a rigid interpretation of the guidelines". The BIA welcomes the recommendations of report author Paul Myners that the guidelines should be replaced to allow for a "case-by-case engagement between a company's directors and shareholders" and that there be a more proactive monitoring of their application, under a new pre-emption group. The current fund-raising thresholds stand at 5% of issued share capital per year, and up to 7.5% over a three-year period. The BIA wants the 5% limit raised to 20%.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts